• Mashup Score: 0

    This Viewpoint discusses how the design of the Centers for Medicare & Medicaid Services (CMS) registry could impact Medicare’s ability to evaluate whether monoclonal antibodies are reasonable and necessary for patients with Alzheimer disease and help physicians understand when the drug is most…

    Tweet Tweets with this article
    • Viewpoint: how the design of the @CMSGov registry could impact Medicare’s ability to evaluate whether monoclonal antibodies are reasonable and necessary for patients with #AlzheimerDisease and help physicians understand when the drug is most beneficial. https://t.co/lTmCGmTyNi

  • Mashup Score: 3

    Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment. Read the related article in . Visit for associated article links.

    Tweet Tweets with this article
    • Neurology Podcast: Drs. Gregg Day & Vijay Ramanan discuss the clinical trial eligibility criteria for lecanemab treatment for participants with early #AlzheimerDisease. Listen now: https://t.co/GcHKz6vHRX @vijaykramanan @mayoclinicneuro @GDay_Neuro https://t.co/8gYd14yV5W

  • Mashup Score: 1

    Background and Objectives Now more than two-thirds of cancer survivors are aged 65 years or older, but evidence about their long-term health is thin. Cancer and its treatments have been linked to accelerated aging, so there is a concern that aging cancer survivors have an increased risk of age-related diseases, including dementia. Methods We examined the risk of dementia among 5-year breast cancer survivors using a matched cohort study design. We included breast cancer survivors aged 50 years and older at diagnosis (n = 26,741) and cancer-free comparison participants (n = 249,540). Women eligible for inclusion in the study were those born 1935–1975 and registered in the Swedish Total Population Register between January 1, 1991, and December 31, 2015. We defined breast cancer survivors as women with an initial breast cancer diagnosis between 1991 and 2005 who survived 5 or more years after their first diagnosis. We assessed all-cause dementia, Alzheimer disease (AD), and vascular dement

    Tweet Tweets with this article
    • In this study, authors examined the risk of all-cause #dementia, vascular dementia, and #AlzheimerDisease in 5-year breast cancer survivors compared with matched comparison participants without a history of cancer: https://t.co/jZcWOlImkt https://t.co/pzjqjexffr

  • Mashup Score: 0

    This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.

    Tweet Tweets with this article
    • .@JAMA_current: Among patients with early symptomatic #AlzheimerDisease and amyloid and tau pathology, #donanemab treatment significantly slowed clinical progression at 76 weeks. #Amyloidosis #TRAILBLAZER-ALZ 2 Randomized Clinical Trial #placebo #outcomes https://t.co/XSfu0mF0EP https://t.co/GqhwZnIQgZ